Shcherbakov A B
Vutr Boles. 1988;27(6):55-8.
The results of a short and a prolonged treatment of Raynaud's syndrome with calcium antagonists are presented. The efficacy of Nifedipin, Verapamil and Fendiline was evaluated in a 14 day treatment of 61 patients with Raynaud's syndrome. Nifedipin and Fendiline was evaluated in a 14 day treatment of 61 patients with Raynaud's syndrome. Nifedipine and Fendiline were most efficient but Fendiline led to more untoward reactions. Verapamil was least efficient and exerted a weak vasoactive action. The influence of the hemocirculation indices on all drugs studied was insignificant. 20 patients with systemic sclerodermia were given 30-60 mg Nifedipin daily in the course of one year and the frequency, duration and expression of the attacks of Raynaud's syndrome decreased practically twice. The study allows the recommendation of Nifedipin as the drug of choice for the treatment of Raynaud's syndrome in the systemic connective tissue diseases.
本文介绍了钙拮抗剂对雷诺氏综合征进行短期和长期治疗的结果。在对61例雷诺氏综合征患者进行的为期14天的治疗中，评估了硝苯地平、维拉帕米和芬地林的疗效。在对61例雷诺氏综合征患者进行的为期14天的治疗中，评估了硝苯地平和芬地林的疗效。硝苯地平和芬地林最为有效，但芬地林会引发更多不良反应。维拉帕米效果最差，血管活性作用较弱。血液流变学指标对所有研究药物的影响不显著。20例系统性硬皮病患者在一年时间里每天服用30 - 60毫克硝苯地平，雷诺氏综合征发作的频率、持续时间和严重程度实际下降了近一半。该研究表明，硝苯地平可作为治疗系统性结缔组织疾病中雷诺氏综合征的首选药物。
